Physician profile
Miranda Engeldinger
NPI 1699456087
$2,424.49
in general payments reported to CMS, 2019-2025
19 companies · $940 in 2025
The $940 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $409 · 2024: $1,076 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.60 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $425.19 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $257.85 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $195.61 | 2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.69 | 2023-2025 | Caplyta |
| Corium, LLC | $165.75 | 2023-2025 | Azstarys |
| Alkermes, INC. | $81.58 | 2024-2025 | Aristada, Lybalvi |
| Biogen, INC. | $67.83 | 2024 | |
| Janssen Pharmaceuticals, INC | $66.46 | 2024-2025 | Spravato |
| Neos Therapeutics, Lp | $63.81 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Neurocrine Biosciences, INC. | $57.82 | 2025 | |
| Axsome Therapeutics, INC. | $51.92 | 2024-2025 | Auvelity |
| Lundbeck LLC | $40.02 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $38.59 | 2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $34.69 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $28.83 | 2025 | Qelbree |
| Almatica Pharma LLC | $16.58 | 2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $14.15 | 2025 | Trintellix |
| Tris Pharma INC | $13.52 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Engeldinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.